Products for Research Use Only
RegisterLogin

Pyrotinib dimaleate

CAT: 0804-HY-104065B-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-104065B-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively[1].
CAS Number
1397922-61-0
Product Name Alternative
SHR-1258 dimaleate
UNSPSC
12352005
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Pyrotinib_dimaleate.html
Concentration
10mM
Purity
98.01
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 106 mg/mL
Smiles
O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)C2=C1)/C=C/[C@@H]5N(C)CCC5.O=C(O)/C=C\C(O)=O.O=C(O)/C=C\C(O)=O
Molecular Formula
C40H39ClN6O11
Molecular Weight
815.22
References & Citations
[1]Li X, et al. Discovery and development of Pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017 Jan 21. pii: S0928-0987 (17) 30043-X.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
EGFR/ErbB1/HER1; ErbB2/HER2
Citation 01
Int J Cancer. 2024 Jul 15;155 (2) :324-338.|Open Life Sci. 2023 Jan 10;18 (1) :20220535.|Biomed Pharmacother. 2024 Nov:180:117523.|Biosci Rep. 2020 Feb 28;40 (2) :BSR20194167.|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Clin Transl Oncol. 2024 May 25.|Int J Biol Macromol. 2023 Jul 1;242 (Pt 2) :124870.|iScience. 2024 Jan 9;27 (2) :108839.|J Exp Clin Cancer Res. 2025 Aug 19;44 (1) :245.|J Med Chem. 2019 May 9;62 (9) :4772-4778.|J Thorac Oncol. 2024 Jan;19 (1) :106-118.|Lung Cancer. 2018 Dec:126:72-79.|Mol Syst Biol. 2024 Jan;20 (1) :28-55.|Nat Cancer. 2025 Jul;6 (7) :1202-1222.|Patent. US 20220175778A1.|Patent. US20210361655A1.|Patent. US20250312348A1.|STAR Protoc. 2024 Apr 16;5 (2) :102987.

Related Products

CatalogName
HY-104065-01Pyrotinib
HY-104065A-01(Rac) -Pyrotinib
HY-B0807A-01Prochlorperazine (dimaleate)
HY-101373AZolantidine (dimaleate)
HY-115371Butaperazine (dimaleate)
HY-B0170A-01Azatadine (dimaleate)
HY-10261A-01Afatinib (dimaleate)
HY-101046-01Quipazine (dimaleate)
HY-101052-01HTMT (dimaleate)
HY-A0211ACarphenazine (dimaleate)

Alternative Products

CatalogName
BUP12739-01Pyrotinib dimaleate
A21756-10Pyrotinib dimaleate 10mg
A21756-100Pyrotinib dimaleate 100mg
A21756-5Pyrotinib dimaleate 5mg
A21756-1Pyrotinib dimaleate 1mg
A21756-50Pyrotinib dimaleate 50mg
A21756-25Pyrotinib dimaleate 25mg
A21756-10mM-DPyrotinib dimaleate 10mM * 1mL in DMSO
BA6328-1Pyrotinib

Popular Products